Publications by the researcher in collaboration with Luisa Ugedo Urruela (61)

2022

  1. Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation

    Frontiers in Pharmacology, Vol. 13

  2. Preferential Modulatory Action of 5-HT2A Receptors on the Dynamic Regulation of Basal Ganglia Circuits

    Journal of Neuroscience, Vol. 43, Núm. 1, pp. 56-67

2021

  1. Dopaminergic denervation impairs cortical motor and associative/limbic information processing through the basal ganglia and its modulation by the CB1 receptor

    Neurobiology of Disease, Vol. 148

  2. The effect of 5-HT1A receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats

    British Journal of Pharmacology, Vol. 178, Núm. 12, pp. 2516-2532

2020

  1. 6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata

    British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 3957-3974

  2. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

2019

  1. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats

    Experimental Neurology, Vol. 322

  2. Cannabinoids differentially modulate cortical information transmission through the sensorimotor or medial prefrontal basal ganglia circuits

    British Journal of Pharmacology, Vol. 176, Núm. 8, pp. 1156-1169

  3. Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia

    International Review of Neurobiology (Academic Press Inc.), pp. 259-279

  4. Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model

    European Neuropsychopharmacology, Vol. 29, Núm. 5, pp. 590-600

  5. Nanodelivery of therapeutic agents in Parkinson's disease

    Progress in Brain Research (Elsevier B.V.), pp. 263-279

2018

  1. Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)

    Molecular Neurobiology

  2. Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212

  3. Nanodelivery of cerebrolysin and rearing in enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 286-299

2017

  1. Activation of Extracellular Signal-Regulated Kinases (ERK 1/2) in the Locus Coeruleus Contributes to Pain-Related Anxiety in Arthritic Male Rats

    International Journal of Neuropsychopharmacology, Vol. 20, Núm. 6, pp. 463-475

  2. Impairment of serotonergic transmission by the antiparkinsonian drug L-DOPA: Mechanisms and clinical implications

    Frontiers in Cellular Neuroscience

  3. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

  4. Zergatik egiten digu alkoholak kalte?

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 31, pp. 21-32

2016

  1. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors

    Experimental Neurology, Vol. 277, pp. 35-45

  2. Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders

    CANNABINOIDS IN HEALTH AND DISEASE (INTECH EUROPE), pp. 59-92